Crosshair is leveraging a novel AI drug discovery platform to create an entirely new class of therapeutics to treat cancer, ageing and other diseases.
Our D-Chain Technology platform enables unrestricted access to the most difficult disease targets and represents an order-of-magnitude step-change in precision targeting compared to the latest immunotherapies. We utilize computational modeling to rapidly design our chain-like therapeutics at low cost, and encode them for delivery in custom engineered gene therapy vectors.
The EcosystemMichael Bruno is a 20 year academia and industry veteran, having held postions at both Yale and Stanford University, specialising in novel drug discovery technologies, before moving into industry seven years ago.
Professor Snyder is Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine at Stanford University. He is a board member, advisor and co-founder of several biotech companies, including Personalis.
Professor Arkin is Chair of Pharmaceutical Chemistry at UC San Franscisco. She is a leader in the development of novel drug discovery technologies and has prior industry experience with Genentech.
Michele Marzola is a serial entrepreneur in the life sciences and has led several biotech companies, including those developing novel therapies in oncology.